Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Cardiff Oncology Q4 2023 GAAP EPS $(0.210) Beats $(0.280) Estimate, Sales $156.000K Beat $37.500K Estimate

Author: Benzinga Newsdesk | February 29, 2024 05:20pm

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.280) by 25 percent. The company reported quarterly sales of $156.000 thousand which beat the analyst consensus estimate of $37.500 thousand by 316.00 percent. This is a 21.88 percent increase over sales of $128.000 thousand the same period last year.

Posted In: CRDF